Compass Pathways submits FDA new drug application for COMP360 psilocybin for treatment-resistant depression

Compass Pathways has completed and submitted a New Drug Application to the U.S. FDA for COMP360 psilocybin for the treatment of treatment-resistant depression.

Detected & updated continuously · Source: Nebula